Δευτέρα 28 Αυγούστου 2017

Two New Therapies Approved for Acute Myeloid Leukemia

FDA has approved two new treatments for some adult patients with acute myeloid leukemia (AML): enasidenib (Idhifa®), which targets the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos®), a two-drug chemotherapy combination encapsulated in liposomes.



http://ift.tt/2vm3qFT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου